or Try an Advanced Search...

    Technical Analysis for EDIT - Editas Medicine, Inc.

    Grade Last Price % Change Price Change
    F 2.39 -1.04% -0.03
    EDIT closed down 2.82 percent on Wednesday, November 20, 2024, on 1.31 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    6 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical EDIT trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish -1.04%
    Lower Bollinger Band Walk Weakness -1.04%
    New 52 Week Low Weakness -1.04%
    Wide Bands Range Expansion -1.04%
    Below Lower BB Weakness -1.04%
    Down 3 Days in a Row Weakness -1.04%
    Down 4 Days in a Row Weakness -1.04%
    Down 5 Days in a Row Weakness -1.04%
    Lower Bollinger Band Touch Weakness -1.04%
    Oversold Stochastic Weakness -1.04%
    Older End-of-Day Signals for EDIT ...

       Recent Intraday Alerts

    Alert Time
    Down 3% about 4 hours ago
    Fell Below Previous Day's Low about 4 hours ago
    Down 2 % about 4 hours ago
    New 52 Week Low about 4 hours ago
    Down 1% about 4 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    EDIT Chart by TradingView
    Basic chart:

    Profile

    As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biology Immune System Genetics Enzymes Genetic Engineering Genome CRISPR DNA Genome Editing Cas9

    Is EDIT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 20 Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)
    Nov 11 CRISPR, Beam, other gene editing names up significantly
    Nov 6 Editas Medicine upgraded at Evercore on CRISPR platform
    Nov 6 Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19%
    Nov 5 Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty
    Nov 5 Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y
    Nov 5 These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
    Nov 5 Editas Medicine Third Quarter 2024 Earnings: Misses Expectations
    Nov 4 Editas downgraded to market perform by Raymond James
    Nov 4 Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates
    See more EDIT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.69
    52 Week Low 2.35
    Average Volume 2,151,112
    200-Day Moving Average 5.24
    50-Day Moving Average 3.26
    20-Day Moving Average 2.97
    10-Day Moving Average 2.85
    Average True Range 0.21
    RSI (14) 31.03
    ADX 17.13
    +DI 15.49
    -DI 33.93
    Chandelier Exit (Long, 3 ATRs) 3.11
    Chandelier Exit (Short, 3 ATRs) 2.99
    Upper Bollinger Bands 3.49
    Lower Bollinger Band 2.44
    Percent B (%b) -0.02
    BandWidth 35.73
    MACD Line -0.20
    MACD Signal Line -0.14
    MACD Histogram -0.0608
    Fundamentals Value
    Market Cap 196.83 Million
    Num Shares 81.7 Million
    EPS -2.69
    Price-to-Earnings (P/E) Ratio -0.90
    Price-to-Sales 25.99
    Price-to-Book 1.69
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.60
    Resistance 3 (R3) 2.60 2.54 2.57
    Resistance 2 (R2) 2.54 2.49 2.54 2.56
    Resistance 1 (R1) 2.47 2.46 2.44 2.47 2.55
    Pivot Point 2.41 2.41 2.40 2.41 2.41
    Support 1 (S1) 2.35 2.36 2.32 2.35 2.27
    Support 2 (S2) 2.29 2.33 2.29 2.26
    Support 3 (S3) 2.22 2.29 2.25
    Support 4 (S4) 2.22